# Phase III Radium 223 mCRPC-PEACE III

> **NCT02194842** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 446 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ra223
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02194842
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2024-02-19
- **Final completion:** 2028-12
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194842, "Phase III Radium 223 mCRPC-PEACE III". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02194842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*